Scholars@Duke publication: Patients with atypical X-linked severe combined immunodeficiency (XSCID) may benefit from hematopoietic stem cell gene therapy.

Patients with atypical X-linked severe combined immunodeficiency (XSCID) may benefit from hematopoietic stem cell gene therapy.

Publication , Journal Article

Puck, JM; Hay, BN; Hsu, AP; Fischer, R; Tsai, E; Uzel, G; Buckley, RH; Malech, HL

Published in: Blood Cells Molecules and Diseases

May 1, 2002

Blood Cells Molecules and Diseases

1079-9796

May 1, 2002

343 / 343

ACADEMIC PRESS INC ELSEVIER SCIENCE

APA

Chicago

ICMJE

MLA

NLM

Puck, J. M., Hay, B. N., Hsu, A. P., Fischer, R., Tsai, E., Uzel, G., … Malech, H. L. (2002). Patients with atypical X-linked severe combined immunodeficiency (XSCID) may benefit from hematopoietic stem cell gene therapy. Blood Cells Molecules and Diseases, 28(3), 343–343.

Puck, J. M., B. N. Hay, A. P. Hsu, R. Fischer, E. Tsai, G. Uzel, R. H. Buckley, and H. L. Malech. “Patients with atypical X-linked severe combined immunodeficiency (XSCID) may benefit from hematopoietic stem cell gene therapy.” Blood Cells Molecules and Diseases 28, no. 3 (May 1, 2002): 343–343.

Puck, J. M., et al. “Patients with atypical X-linked severe combined immunodeficiency (XSCID) may benefit from hematopoietic stem cell gene therapy.” Blood Cells Molecules and Diseases, vol. 28, no. 3, ACADEMIC PRESS INC ELSEVIER SCIENCE, May 2002, pp. 343–343.

Puck JM, Hay BN, Hsu AP, Fischer R, Tsai E, Uzel G, Buckley RH, Malech HL. Patients with atypical X-linked severe combined immunodeficiency (XSCID) may benefit from hematopoietic stem cell gene therapy. Blood Cells Molecules and Diseases. ACADEMIC PRESS INC ELSEVIER SCIENCE; 2002 May 1;28(3):343–343.

Blood Cells Molecules and Diseases

1079-9796

May 1, 2002

343 / 343

ACADEMIC PRESS INC ELSEVIER SCIENCE